Today’s Top Stories: Moderna, Merck, Marvell and SK Hynix Make Big Moves on Wall Street

TLDR

• Moderna and Merck’s personalized mRNA cancer vaccine met all endpoints in a Phase 3 melanoma trial
• Marvell Technology struck an expanded AI chip deal with Google worth a potential $120 billion through 2033
• Estée Lauder surged around 18% after issuing a stronger-than-expected profit forecast for fiscal 2027
• SK Hynix announced a $28.6 billion share buyback, one of the largest in semiconductor history
• Merck shares jumped 10-11% on the back of the successful Keytruda combination trial results

Wednesday was one of the busiest sessions on Wall Street in recent weeks, with major stock moves across biotech, semiconductors, beauty and AI chips.

Moderna and Merck Score Landmark Cancer Vaccine Results

The biggest story of the day came from Moderna and Merck. The two companies announced positive late-stage results for a personalized mRNA cancer vaccine used alongside Merck’s Keytruda drug.

The treatment met both primary and secondary endpoints in a Phase 3 melanoma trial. It is one of the strongest pieces of evidence yet that mRNA technology, best known from COVID-19 vaccines, can be applied to cancer treatment.

… Continue reading the full article at the original source below.